Emcure Pharmaceuticals Limited (NSE: EMCURE) has announced its Q1 FY27 results, showcasing a robust performance with revenue up 22.8% and profit after tax (PAT) surging 36.2%. The company’s strong all-round performance is driven by increased contribution from the international business, which saw a 34.2% YoY growth.

Leadership Changes

The company also announced significant leadership changes. Mr. Satish Mehta will take over as Chairman in addition to his existing role as Managing Director & CEO, effective post the upcoming AGM. Mr. Samit Mehta has been appointed as COO, getting broader oversight of the Group’s R&D, operations, and licensing activities.

Financial Highlights

The company reported a revenue of INR 25,804 million with an EBITDA margin of 19.7% and PAT margin of 11.3%. The international business, contributing 58% to the total revenue, showed strong growth across Europe, RoW, and Canada. Domestic revenue grew by 10.2%, reflecting a resilient performance.

Emcure Pharmaceuticals Limited continues to build on its strategic initiatives, aiming for sustained growth over the medium term.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Emcure gains 17.7% over three months and trades near its 52-week highs. The business compounds revenue at 15.8% and profits at 20.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 93% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 15.8% and profits at 20.2%, with D/E of 0.22. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.99 premium is usually justified. Check Fundamentals of Emcure Pharmaceuticals Limited.

Emcure Pharmaceuticals Limited (EMCURE) announced today that Poviztra®, its co-marketed brand of innovator semaglutide (rDNA origin), will now be available for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3), following the Central Drugs Standard Control Organization’s (CDSCO) approval. This approval addresses a significant unmet medical need for patients with MASH, a progressive liver disease with limited treatment options. Poviztra® is manufactured and imported from Novo Nordisk’s European manufacturing facility and contains innovator rDNA-origin semaglutide. Through its subsidiary Zuventus Healthcare’s strong gastroenterology and hepatology portfolio, Emcure will help expand MASH awareness, diagnosis, and treatment.

CDSCO Approval and Clinical Benefits

The approval makes the innovator molecule from Novo Nordisk, the first and only GLP-1 receptor agonist approved in India for the treatment of the disease. It enables Emcure and its subsidiaries to offer the new indication through Poviztra®, expanding access to innovator semaglutide for patients living with a progressive liver disease that has long faced limited treatment options. The approval is supported by results from the global Phase III ESSENCE trial, in which semaglutide demonstrated resolution of steatohepatitis in 63% of patients and improvement in liver fibrosis in 37% of patients. One in three patients achieved both resolution of steatohepatitis and improvement in liver fibrosis, highlighting semaglutide’s potential to address the underlying disease in addition to its established metabolic benefits.

Company’s Commitment to Innovation

Satish Mehta, Chief Executive Officer & Managing Director, Emcure Pharmaceuticals Limited, said: ‘The approval for MASH marks an important milestone for patients living with a serious and often underdiagnosed liver disease. We are pleased to make this important new indication available through Poviztra®, further strengthening our commitment to bringing globally validated, innovative therapies to patients in India. We look forward to working closely with healthcare professionals to improve awareness, encourage earlier diagnosis, and expand access to evidence-based treatment for people living with MASH.’ The addition of the MASH indication for Poviztra® further strengthens the company’s commitment to addressing complex metabolic diseases through innovative, science-led therapies while supporting physicians in improving long-term patient outcomes.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Emcure holds in the upper half of its 52-week range, a sign the market backs the stock. The business compounds revenue at 15.8% and profits at 20.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 76% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 15.8% and profits at 20.2%, with D/E of 0.22. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.81 premium is usually justified. Check Fundamentals of Emcure Pharmaceuticals Limited.

Emcure Pharmaceuticals Limited (NSE: EMCURE) today announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited (“Gennova”), alongside a leadership transition, as it sharpens its focus as a biologics and biosimilars company. Emcure is acquiring the entire 12.05% minority stake in Gennova held by Dr. Sanjay Singh and others, taking its ownership to 100% and making Gennova a wholly owned subsidiary.

Leadership Transition

Gennova will be led by Mr. Samit Mehta and will focus on its biologics franchise — Elaxim®/TENECTASE®, Vintor®, Xgrast®/PEGEX® and Hamsyl® — biosimilars development, and adjacent therapeutic platforms, leveraging its established mammalian and microbial biomanufacturing platforms.

Strategic Focus

Commenting on the announcement, Mr. Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals Limited, said: “We thank Dr. Sanjay Singh for his nearly two decades of exceptional scientific leadership at Gennova. His stewardship has built platforms, products, and a culture that will continue to fulfil Gennova’s mission of transforming healthcare. With this stake acquisition, we simplify Gennova’s ownership, sharpen its strategic focus, and position it under Mr. Samit Mehta’s leadership for its next phase of growth in biologics and biosimilars.”

Future Outlook

Mr. Samit Mehta, Whole Time Director & CEO, Gennova Biopharmaceuticals Limited, said: “As part of the One Emcure framework, Gennova will continue to anchor the Group’s biologics and biosimilars capabilities. Our work will complement Emcure’s broader R&D and pipeline priorities, with a focus on execution, quality and disciplined development across our chosen therapy areas.” The transaction is not expected to have a material impact on Emcure’s consolidated financials or its capital allocation framework. The Company’s deleveraging trajectory, capex plans and R&D investment plans remain unchanged.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Emcure rises 13.4% over three months, with buying pressure holding steady. The business compounds revenue at 15.8% and profits at 20.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 81% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 15.8% and profits at 20.2%, with D/E of 0.22. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.84 premium is usually justified. Check Fundamentals of Emcure Pharmaceuticals Limited.